GLP-1: target for a new class of antidiabetic agents?
Edwards
C Mark B
CM
Hillingdon Hospital, Uxbridge UB8 3NN, UK. c.m.b.edwards@imperial.ac.uk
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000077270:Exenatide; D005934:Glucagon / Q000031:analogs & derivatives / Q000502:physiology* / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide; D010446:Peptide Fragments / Q000502:physiology*; D010455:Peptides / Q000627:therapeutic use*; D011498:Protein Precursors / Q000502:physiology*; D014688:Venoms / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077270:Exenatide